136 related articles for article (PubMed ID: 23354042)
1. Clostridium butyricum MIYAIRI 588 shows antitumor effects by enhancing the release of TRAIL from neutrophils through MMP-8.
Shinnoh M; Horinaka M; Yasuda T; Yoshikawa S; Morita M; Yamada T; Miki T; Sakai T
Int J Oncol; 2013 Mar; 42(3):903-11. PubMed ID: 23354042
[TBL] [Abstract][Full Text] [Related]
2. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors.
Kamat AM; Tharakan ST; Sung B; Aggarwal BB
Cancer Res; 2009 Dec; 69(23):8958-66. PubMed ID: 19903839
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity.
Ludwig AT; Moore JM; Luo Y; Chen X; Saltsgaver NA; O'Donnell MA; Griffith TS
Cancer Res; 2004 May; 64(10):3386-90. PubMed ID: 15150089
[TBL] [Abstract][Full Text] [Related]
4. PMN and anti-tumor immunity--the case of bladder cancer immunotherapy.
Brincks EL; Risk MC; Griffith TS
Semin Cancer Biol; 2013 Jun; 23(3):183-9. PubMed ID: 23410637
[TBL] [Abstract][Full Text] [Related]
5. The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder.
Rosevear HM; Lightfoot AJ; O'Donnell MA; Griffith TS
Cancer Metastasis Rev; 2009 Dec; 28(3-4):345-53. PubMed ID: 19967427
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L.
Kemp TJ; Ludwig AT; Earel JK; Moore JM; Vanoosten RL; Moses B; Leidal K; Nauseef WM; Griffith TS
Blood; 2005 Nov; 106(10):3474-82. PubMed ID: 16037389
[TBL] [Abstract][Full Text] [Related]
7. Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer.
Simons MP; Nauseef WM; Griffith TS
Immunol Res; 2007; 39(1-3):79-93. PubMed ID: 17917057
[TBL] [Abstract][Full Text] [Related]
8. Role of neutrophils in BCG immunotherapy for bladder cancer.
Simons MP; O'Donnell MA; Griffith TS
Urol Oncol; 2008; 26(4):341-5. PubMed ID: 18593617
[TBL] [Abstract][Full Text] [Related]
9. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
10. Fas ligand and TNF-related apoptosis-inducing ligand induction on infiltrating lymphocytes in bladder carcinoma by bacillus Calmette-Guérin treatment.
Mehmut M; Takeda K; Abe M; Ogata H; Hirose S; Okumura K; Fujime M
Urol Int; 2005; 75(1):80-7. PubMed ID: 16037714
[TBL] [Abstract][Full Text] [Related]
11. Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils.
Simons MP; Moore JM; Kemp TJ; Griffith TS
Infect Immun; 2007 Mar; 75(3):1265-71. PubMed ID: 17194806
[TBL] [Abstract][Full Text] [Related]
12. MUC5AC protects pancreatic cancer cells from TRAIL-induced death pathways.
Hoshi H; Sawada T; Uchida M; Iijima H; Kimura K; Hirakawa K; Wanibuchi H
Int J Oncol; 2013 Mar; 42(3):887-93. PubMed ID: 23292004
[TBL] [Abstract][Full Text] [Related]
13. Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist.
Griffith TS; Kucaba TA; O'Donnell MA; Burns J; Benetatos C; McKinlay MA; Condon S; Chunduru S
Apoptosis; 2011 Jan; 16(1):13-26. PubMed ID: 20734142
[TBL] [Abstract][Full Text] [Related]
14. Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients.
Tanaka H; Ito T; Kyo T; Kimura A
Eur J Haematol; 2007 May; 78(5):389-98. PubMed ID: 17432976
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
Fang F; Wang AP; Yang SF
Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated TRAIL expression and downregulation of Bcl-2 expression suppresses non-small cell lung cancer growth in vitro and in vivo.
Zhang H; Sui A; Wang Z; Liu S; Yao R
Int J Mol Med; 2012 Aug; 30(2):358-64. PubMed ID: 22614533
[TBL] [Abstract][Full Text] [Related]
17. An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells.
Nyormoi O; Mills L; Bar-Eli M
Cell Death Differ; 2003 May; 10(5):558-69. PubMed ID: 12728254
[TBL] [Abstract][Full Text] [Related]
18. Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells.
Yano K; Horinaka M; Yoshida T; Yasuda T; Taniguchi H; Goda AE; Wakada M; Yoshikawa S; Nakamura T; Kawauchi A; Miki T; Sakai T
Int J Oncol; 2011 Feb; 38(2):365-74. PubMed ID: 21165560
[TBL] [Abstract][Full Text] [Related]
19. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
20. The role of granulocytes following intravesical BCG prophylaxis.
Siracusano S; Vita F; Abbate R; Ciciliato S; Borelli V; Bernabei M; Zabucchi G
Eur Urol; 2007 Jun; 51(6):1589-97; discussion 1597-9. PubMed ID: 17222501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
